effect overlay
activetrials
Dementia
Dementia
TRAILBLAZER - Donanemab in Alzheimer's

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
 

HREC: 2021.066
Principal Investigator: Prof Amy Brodtmann
Coordinator contact: Sophie Robinson
Funding: Commercial
Dementia
Dementia
RETHINK

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-Week Study Evaluating the Safety and Efficacy of Simufilam 100 Mg Tablets in Subjects With Mild-to-Moderate Alzheimer’s Disease
 

HREC: 2022.215
Principal Investigator: Dr Christopher Kyndt
Coordinator contact: Lesley-Anne Attard
Funding: Commercial
Epilepsy
Epilepsy
Genetics of Drug Rash in EP

Genetics of Drug Rash in EP

HREC: 2015.073
Principal Investigator: Prof Patrick Kwan
Coordinator contact: Dr Marian Todaro
Funding: Non-Commercial
Epilepsy
Epilepsy
Drug Resistant Epilepsy

Drug Resistant Epilepsy

HREC: 2019.321
Principal Investigator: Prof Patrick Kwan
Coordinator contact:
Funding: Non-Commercial
Epilepsy
Epilepsy
ENIGMA

Use of deep learning to support clinical decision making for resective surgery in drug resistant focal epilepsy

HREC: 2022.355
Principal Investigator: Dr John-Paul Nicolo
Coordinator contact: Merran Courtney
Funding: Non-Commercial